Who are Icosapent ethyl (IPE)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epanova, Omacor + simvastatin, Antara (fenofibrate) + Lovaza, THYROX (Atlantic krill oil)., Product 3 - Standard Fish Oil Triglyceride, Omacor®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icosapent-ethyl-ipe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Icosapent ethyl (IPE) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Icosapent ethyl (IPE) (Icosapent ethyl (IPE)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid. Area: Cardiovascular.

phase 3 Omega-3 fatty acid Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Icosapent ethyl (IPE) (Icosapent ethyl (IPE)) — Estudios Clínicos Latino América. Icosapent ethyl is a purified ethyl ester of eicosapentaenoic acid (EPA) that reduces triglyceride levels and modulates lipid metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Icosapent ethyl (IPE) TARGET	Icosapent ethyl (IPE)	Estudios Clínicos Latino América	phase 3	Omega-3 fatty acid
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
Omacor + simvastatin	Omacor + simvastatin	Provident Clinical Research	marketed	Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin)	VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)
Antara (fenofibrate) + Lovaza	Antara (fenofibrate) + Lovaza	GlaxoSmithKline	marketed	Fibrate + Omega-3 fatty acid combination	PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids)
THYROX (Atlantic krill oil).	THYROX (Atlantic krill oil).	Poznan University of Physical Education	marketed	Dietary supplement / Omega-3 fatty acid supplement
Product 3 - Standard Fish Oil Triglyceride	Product 3 - Standard Fish Oil Triglyceride	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement
Omacor®	Omacor®	Hospital Universitari Vall d'Hebron Research Institute	marketed	Omega-3 fatty acid	Hepatic triglyceride synthesis pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid class)

Estudios Clínicos Latino América · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
S.L.A. Pharma AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Icosapent ethyl (IPE) — Competitive Intelligence Brief. https://druglandscape.com/ci/icosapent-ethyl-ipe. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing